Emerging agents for the treatment of mantle cell lymphoma

Expert Review of Anticancer Therapy

Volumn 12, Issue 9, 2012, Pages 1205-1215

  Camara Clayette, Valérie ^a,b   Hermine, Olivier ^c   Ribrag, Vincent ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

bortezomib; emerging agent; high dose therapy; mantle cell lymphoma; mTOR AKT; targeted therapy; temsirolimus; therapy

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CARMUSTINE; CD19 ANTIBODY; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FLAVOPIRIDOL; FLUDARABINE; GEMCITABINE; IDELALISIB; IMMUNOMODULATING AGENT; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MELPHALAN; METHOTREXATE; MITOXANTRONE; MONOCLONAL ANTIBODY; OBINUTUZUMAB; PREDNISONE; RITUXIMAB; SAR 3419; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ADD ON THERAPY; ANEMIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CHRONIC LYMPHATIC LEUKEMIA; CONSENSUS; CONSTIPATION; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; FATIGUE; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERGLYCEMIA; INDUCTION CHEMOTHERAPY; LOW DRUG DOSE; MANTLE CELL LYMPHOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PATIENT CARE; PERIPHERAL NEUROPATHY; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; THROMBOCYTOPENIA;

ADULT; AGE FACTORS; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CYTARABINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, INVESTIGATIONAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, MANTLE-CELL; MOLECULAR TARGETED THERAPY; PROGNOSIS; PYRAZINES; RECURRENCE; SALVAGE THERAPY; SIROLIMUS; SURVIVAL ANALYSIS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; WATCHFUL WAITING;

EID: 84867935566     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.99     Document Type: Review

References (86)

1. Schmidt C, Dreyling M. Therapy of mantle cell lymphoma: current standards and future strategies. Hematol. Oncol. Clin. North Am. 22(5), 953-63, ix (2008).
2. NCCN Clinical Practice Guidelines in Oncology, Non-Hodgkin's Lymphomas. V1.2010 (22 December 2009).
3. Bertoni F, Ponzoni M. The cellular origin of mantle cell lymphoma. Int. J. Biochem. Cell Biol. 39(10), 1747-1753 (2007). (Pubitemid 47321342)
4. Jaffe ES, Harris NL, Stein H et al. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, France (2001).
5. Wlodarska I, Dierickx D, Vanhentenrijk V et al. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood 111(12), 5683-5690 (2008).
6. Walsh SH, Thorsélius M, Johnson A et al. Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. Blood 101(10), 4047-4054 (2003). (Pubitemid 36857885)
7. Thorsélius M, Walsh S, Eriksson I et al. Somatic hypermutation and V(H) gene usage in mantle cell lymphoma. Eur. J. Haematol. 68(4), 217-224 (2002). (Pubitemid 34717822)
8. Martin P, Chadburn A, Christos P et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J. Clin. Oncol. 27(8), 1209-1213 (2009).
9. Orchard J, Garand R, Davis Z et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 101(12), 4975-4981 (2003). (Pubitemid 36857762)
10. Fernàndez V, Salamero O, Espinet B et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 70(4), 1408-1418 (2010).
11. de Guibert S, Jaccard A, Bernard M, Turlure P, Bordessoule D, Lamy T. Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma. Haematologica 91(3), 425-426 (2006).
12. Dreger P, Rieger M, Seyfarth B et al. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. Haematologica 92(1), 42-49 (2007). (Pubitemid 46237555)
13. Dreyling M, Weigert O, Hiddemann W, European MCL Network. Current treatment standards and future strategies in mantle cell lymphoma. Ann. Oncol. 19(Suppl. 4), iv41-iv44 (2008).
14. Dreyling MH, Hoster E, Van Hoof A et al. Early consolidation with myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission in mantle cell lymphoma: long term follow up of a randomized trial. ASH Annual Meeting Abstracts 112, 769 (2008).
15. Howard OM, Gribben JG, Neuberg DS et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J. Clin. Oncol. 20(5), 1288-1294 (2002). (Pubitemid 34177435)
16. Lefrère F, Delmer A, Levy V, Delarue R, Varet B, Hermine O. Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. Haematologica 89(10), 1275-1276 (2004). (Pubitemid 39390461)
17. Tam CS, Bassett R, Ledesma C et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 113(18), 4144-4152 (2009).
18. Romaguera JE, Fayad LE, McLaughlin P et al. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. Br. J. Haematol. 151(1), 47-53 (2010).
19. Geisler CH, Kolstad A, Laurell A et al. Nordic Lymphoma Group. Long-term progression-free survival of mantle cell lymphoma after intensive frontline immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized Phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112(7), 2687-2693 (2008).
20. Schulz H, Bohlius JF, Trelle S et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J. Natl Cancer Inst. 99(9), 706-714 (2007). (Pubitemid 47078732)
21. Rule S, Smith P, Johnson PW et al. The addition of rituximab to fludarabine and cyclophosphamide (FC) improves overall survival in newly diagnosed mantle cell lymphoma (MCL): results of the randomised UK NationalCancer Research Institute (NCRI) trial. ASH Annual Meeting Abstracts 118, 440 (2011).
22. Dreyling M, Lenz G, Hoster E et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 105(7), 2677-2684 (2005). (Pubitemid 40450320)
23. Lefrère F, Delmer A, Suzan F et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 16(4), 587-593 (2002). (Pubitemid 34449738)
24. Lenz G, Dreyling M, Hoster E et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low grade Lymphoma Study Group (GLSG). J. Clin. Oncol. 23(9), 1984-1992 (2005). (Pubitemid 46211378)
25. Delarue R, Haioun C, Ribrag V et al. RCHOP and RDHAP followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): final results of a Phase II study from the GELA. ASH Annual Meeting Abstracts 112, 581 (2008).
26. Hermine O, Hoster E, Walewski J et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL younger trial of the European mantle cell lymphoma network (MCL net). ASH Annual Meeting Abstracts 116, 110 (2010).
27. Andersen NS, Pedersen LB, Laurell A et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J. Clin. Oncol. 27(26), 4365-4370 (2009).
28. Romaguera JE, Fayad LE, Feng L et al. Ten-year follow-up after intense chemoimmunotherapy with rituximabhyper- CVAD alternating with rituximabhigh dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br. J. Haematol. 150(2), 200-208 (2010).
29. Epner EM, Unger J, Miller T et al. A multi center trial of hyperCVAD+rituxan in patients with newly diagnosed mantle cell lymphoma. ASH Annual Meeting Abstracts 110, 387 (2007).
30. Kluin-Nelemans HC, Doorduijn JK. Treatment of elderly patients with mantle cell lymphoma. Semin. Hematol. 48(3), 208-213 (2011).
31. Robinson KS, Williams ME, van der Jagt RH et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J. Clin. Oncol. 26, 4473-4479 (2008).
32. Rummel MJ, Al-Batran SE, Kim SZ et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J. Clin. Oncol. 23(15), 3383-3389 (2005).
33. Weide R, Hess G, Köppler H et al. German Low grade Lymphoma Study Group. High anti-lymphoma activity of bendamustine/ mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolentlymphomas and mantle cell lymphomas. A multicenter Phase II study of the German Low grade Lymphoma Study Group (GLSG). Leuk. Lymphoma 48(7), 1299-1306 (2007).
34. Forstpointner R, Unterhalt M, Dreyling M et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108, 4003-4008 (2006). (Pubitemid 44920177)
35. Rummel MJ, Niederle N, Maschmeyer G et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): updated results from the StiL NHL1 study. ASCO Meeting Abstracts 30, 3 (2012).
36. Visco C, Castegnaro S, Chieregato K et al. The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines. Blood Cells Mol. Dis. 48(1), 68-75 (2012).
37. Morschhauser F, Depil S, Jourdan E et al. Phase II study of gemcitabinedexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma. Ann. Oncol. 18(2), 370-375 (2007). (Pubitemid 46331214)
38. Rodríguez J, Gutierrez A, Palacios A et al. Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma. Leuk. Lymphoma 48(11), 2172-2178 (2007). (Pubitemid 350107692)
39. Belch A, Kouroukis CT, Crump M et al. A Phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann. Oncol. 18(1), 116-121 (2007). (Pubitemid 46152510)
40. Goy A, Younes A, McLaughlin P et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 23, 667-675 (2005). (Pubitemid 46224166)
41. O'Connor OA, Wright J, Moskowitz C et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J. Clin. Oncol. 23, 676-684 (2005). (Pubitemid 46237441)
42. Strauss SJ, Maharaj L, Hoare S et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J. Clin. Oncol. 24(13), 2105-2112 (2006). (Pubitemid 46622122)
43. Fisher RI, Bernstein SH, Kahl BS et al. Multicenter Phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 24(30), 4867-4874 (2006). (Pubitemid 46655613)
44. Goy A, Bernstein SH, Kahl BS et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter Phase 2 PINNACLE study. Ann. Oncol. 20(3), 520-525 (2009).
45. Baiocchi RA, Alinari L, Lustberg ME et al. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer 117(11), 2442-2451 (2011).
46. Chiappella A, Pregno P, Zinzani PL et al. Weekly infusion of bortezomib in combination with rituximab in relapsed/ refractory indolent non-follicular and mantle cell lymphoma is safe and effective: two-years analysis of Phase II trial BRIL06 of intergruppo italiano linfomi (IIL). ASH Annual Meeting Abstracts 116, 3965 (2010).
47. Lamm W, Kaufmann H, Raderer M et al. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapyrefractory mantle cell lymphoma. Haematologica 96(7), 1008-1014 (2011).
48. Friedberg JW, Vose JM, Kelly JL et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/ refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 117(10), 2807-2812 (2011).
49. Kouroukis CT, Fernandez LA, Crump M et al. A Phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). Leuk. Lymphoma 52(3), 394-399 (2011).
50. Weigert O, Weidmann E, Mueck R et al. A novel regimen combining high dose cytarabine and bortezomib has activity in multiply-relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study. Leuk. Lymphoma 50(5), 716-722 (2009).
51. Ruan J, Martin P, Furman RR et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J. Clin. Oncol. 29(6), 690-697 (2011).
52. Chang JE, Peterson C, Choi S et al. VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. Br. J. Haematol. 155(2), 190-197 (2011).
53. Dal Col J, Zancai P, Terrin L et al. Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood 111(10), 5142-5151 (2008).
54. Rudelius M, Pittaluga S, Nishizuka S et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 108(5), 1668-1676 (2006). (Pubitemid 44316136)
55. Hara K, Maruki Y, Long X et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110(2), 177-189 (2002). (Pubitemid 34876546)
56. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307(5712), 1098-1101 (2005). (Pubitemid 40262113)
57. Feldman ME, Apsel B, Uotila A et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7(2), e38 (2009).
58. Yu K, Toral-Barza L, Shi C et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 69(15), 6232-6240 (2009).
59. Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis GZ, Medeiros LJ. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am. J. Pathol. 169(6), 2171-2180 (2006). (Pubitemid 351181976)
60. Haritunians T, Mori A, O'Kelly J, Luong QT, Giles FJ, Koeffler HP. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 21(2), 333-339 (2007). (Pubitemid 46158128)
61. Hipp S, Ringshausen I, Oelsner M, Bogner C, Peschel C, Decker T. Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells. Haematologica 90(10), 1433-1434 (2005). (Pubitemid 41503659)
62. Yazbeck VY, Buglio D, Georgakis GV et al. Temsirolimus downregulates p21 withoutaltering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp. Hematol. 36(4), 443-450 (2008). (Pubitemid 351384743)
63. Psyrri A, Papageorgiou S, Liakata E et al. Phosphatidylinositol 3́-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin. Cancer Res. 15, 5724-5732 (2009).
64. Ansell SM, Inwards DJ, Rowland KM Jr et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a Phase 2 trial in the North Central Cancer Treatment Group. Cancer 113(3), 508-514 (2008).
65. Witzig TE, Geyer SM, Ghobrial I et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J. Clin. Oncol. 23(23), 5347-5356 (2005). (Pubitemid 46206988)
66. Hess G, Herbrecht R, Romaguera J et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 27, 3822-3829 (2009).
67. Ansell SM, Tang H, Kurtin PJ et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a Phase 2 study. Lancet Oncol. 12(4), 361-368 (2011).
68. Renner C, Zinzani PL, Gressin R et al. A multi-center Phase II study (SAKK 36/06) of single agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. ASH Annual Meeting Abstracts 116, 2803 (2010).
69. Witzig TE, Reeder CB, LaPlant BR et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 25(2), 341-347 (2011).
70. O'Connor OA, Popplewell L, Winter JN et al. PILLAR-1: preliminary results of a Phase II study of mTOR inhibitor everolimus in patients with mantle cell lymphoma (MCL) who are refractory or intolerant to bortezomib. ASH Annual Meeting Abstracts 116, 3963 (2010).
71. Kahl B, Byrd JC, Flinn IW et al. Clinical safety and activity in a Phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110Δ, in patients with relapsed or refractory non-Hodgkin lymphoma. ASH Annual Meeting Abstracts 116, 1777 (2010).
72. Damaj G, Lefrère F, Delarue R, Varet B, Furman R, Hermine O. Thalidomide therapy induces response in relapsed mantle cell lymphoma. Leukemia 17(9), 1914-1915 (2003). (Pubitemid 37185274)
73. Kaufmann H, Raderer M, Wöhrer S et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/ refractory mantle cell lymphoma. Blood 104(8), 2269-2271 (2004). (Pubitemid 39331822)
74. Wilson EA, Jobanputra S, Jackson R, Parker AN, McQuaker IG. Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case report. Br. J. Haematol. 119(1), 128-130 (2002). (Pubitemid 35176511)
75. Habermann TM, Lossos IS, Justice G et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br. J. Haematol. 145(3), 344-349 (2009).
76. Witzig TE, Vose JM, Zinzani PL et al. An international Phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann. Oncol. 22(7), 1622-1627 (2011).
77. Ahmadi T, Chong EA, Gordon A et al. Phase II trial of lenalidomide- dexamethasone-rituximab in relapsed or refractory indolent B-cell or mantle cell lymphomas resistant to rituximab. ASH Annual Meeting Abstracts 116, 3962 (2010).
78. Zaja F, De Luca S, Vitolo U et al. Salvage treatment with lenalidomide and dexamethasone in patients with relapsed refractory mantle cell lymphoma: clinical results and modifications of angiogenic biomarkers. ASH Annual Meeting Abstracts 116, 966 (2010).
79. Jerkeman M, Kolstad A, Laurell A et al. Lenalidomide, bendamustine, and rituximab as first-line therapy for patients >65 years with mantle cell lymphoma: results from the Phase I portion of the Nordic Lymphoma Group MCL4 (LENA-BERIT) trial. ASH Annual Meeting Abstracts 118, 2700 (2011).
80. Cartron G, Thieblemont C, Solal-Celigny P et al. Promising efficacy with the new anti-cd20 antibody ga101 in heavily pre-treated NHL patients - first results from a Phase II study in patients with relapsed/refractory DLBCL and MCL. ASH Annual Meeting Abstracts 116, 2878 (2010).
81. Coiffier B, Ribrag V, Dupuis J et al. Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). ASCO Meeting Abstracts 29, 8017 (2011).
82. Holkova B, Perkins EB, Ramakrishnan V et al. Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clin. Cancer Res. 17(10), 3388-3397 (2011).
83. Lin TS, Blum KA, Fischer DB et al. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J. Clin. Oncol. 28(3), 418-423 (2010).
84. Fowler N, Sharman JP, Smith SM et al. The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: results from a Phase I study. ASH Annual Meeting Abstracts 116, 964 (2010).
85. Wang L, Martin P, Blum KA et al. The Bruton's tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously treated mantle cell lymphoma (MCL): preliminary results of a Phase II trial. ASH Annual Meeting Abstracts 118, 442 (2011).
86. James RG, Biechele TL, Conrad WH et al. Bruton's tyrosine kinase revealed as a negative regulator of Wnt-beta-catenin signaling. Sci. Signal. 2(72), ra25 (2009).